The SOL Capital Management CO reached $264,000 position of Sanofi (SNY)

The SOL Capital Management CO reached $264,000 position  of Sanofi (SNY)

SOL Capital Management CO lowered its position in shares of Sanofi (NYSE:SNY) by 1.6% during the second quarter, according to its most recent filing with the SEC. The fund owned 6,300 shares of the company’s stock after selling 100 shares during the period. SOL Capital Management CO’s holdings in Sanofi were worth $264,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the stock. Rehmann Capital Advisory Group boosted its stake in shares of Sanofi by 0.5% in the second quarter. Rehmann Capital Advisory Group now owns 5,571 shares of the company’s stock worth $233,000 after buying an additional 26 shares during the period. First Manhattan Co. boosted its stake in shares of Sanofi by 0.6% in the second quarter. First Manhattan Co. now owns 19,281 shares of the company’s stock worth $806,000 after buying an additional 113 shares during the period. JFS Wealth Advisors LLC boosted its stake in shares of Sanofi by 3.5% in the second quarter. JFS Wealth Advisors LLC now owns 3,961 shares of the company’s stock worth $166,000 after buying an additional 134 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Sanofi by 0.6% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 33,104 shares of the company’s stock worth $1,329,000 after buying an additional 213 shares during the period. Finally, 1st Global Advisors Inc. boosted its stake in shares of Sanofi by 1.9% in the second quarter. 1st Global Advisors Inc. now owns 25,710 shares of the company’s stock worth $1,076,000 after buying an additional 479 shares during the period. Hedge funds and other institutional investors own 9.37% of the company’s stock.

Sanofi (NYSE:SNY) traded down 1.06% during midday trading on Monday, hitting $37.35. 2,024,179 shares of the stock traded hands. The stock has a market cap of $96.14 billion, a PE ratio of 20.85 and a beta of 0.98. The company has a 50-day moving average of $38.65 and a 200-day moving average of $40.40. Sanofi has a 12 month low of $37.20 and a 12 month high of $51.88.

Several equities analysts have recently issued reports on SNY shares. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Sanofi in a research report on Thursday, September 15th. TheStreet lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Monday, August 22nd. Zacks Investment Research lowered Sanofi from a “hold” rating to a “sell” rating in a research report on Wednesday, August 3rd. Berenberg Bank reaffirmed a “hold” rating and issued a $93.00 price target on shares of Sanofi in a research report on Monday, August 15th. Finally, BNP Paribas raised Sanofi from an “underperform” rating to a “neutral” rating in a research report on Tuesday, September 13th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company. Sanofi presently has a consensus rating of “Hold” and a consensus target price of $60.50.

Sanofi Company Profile

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

Related posts

Leave a Comment